Respiratory Host-Pathogen Interaction

Grant number: 101057129

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2022
    2026
  • Known Financial Commitments (USD)

    $7,137,450
  • Funder

    European Commission
  • Principal Investigator

    Krause Tyra
  • Research Location

    Denmark
  • Lead Research Institution

    STATENS SERUM INSTITUT
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Lower respiratory tract infections resulting from seasonal epidemics and pandemics are among the leading causes of death globally. There is a paucity of treatment options for viral respiratory pathogens and patient care remains largely supportive. This underscores a desperate need for identifying novel targets for prophylactic/treatment interventions and early prediction models of disease outcome to personalise treatment. The REACT consortium ? uniting high-level experts in virology, immunology, clinical medicine, epidemiology, and bioinformatics ? will assess genotypic, high-dimensional immunophenotypic, demographic and clinical data in the context of disease course to define host-pathogen interactions of viral respiratory tract infections, focusing on the predominating viruses i.e. influenza, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In characterised, ethnically diverse clinical cohorts comprising patients with varying disease severities, we will genotype both virus and host, map deep immunological phenotypes spanning cellular, humoral and innate immunity, and characterise host responses in human nasal epithelial organoid models following viral infection. Novel bioinformatics approaches that include knowledge discovery and machine learning will be used to integrate and analyse multidisciplinary datasets to assess the individual and combined impact of factors on disease phenotype. Information on the deep characterisation of the dynamics of the immune responses to the chosen viruses and identified factors critical for viral control and immune protection will be made available on a dedicated project website to clinicians, researchers, health authorities, and public. This will provide direct and immediate access to our findings for further development of personalised treatment, therapeutic targets and vaccines in future trials and clinical practice to improve the wellbeing of the EU population and beyond.

Publicationslinked via Europe PMC

Last Updated:43 minutes ago

View all publications at Europe PMC

Nationwide longitudinal study reveals impact of both national restriction levels and genetic risk factors on loneliness during the COVID-19 pandemic.

SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19.

Boosting SARS-CoV-2 immunity in immunocompromised individuals.

Author Correction: Human circulating and tissue-resident memory CD8+ T cells.

Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states.

Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox.

Booster mRNA vaccination post-SARS-CoV-2 infection enhances functional qualities of T cell immunity

Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age.